Sleepio

New Research Demonstrates Clinical Effectiveness of Digital Treatment at Improving Insomnia and Comorbid Mental and Physical Health Issues

Retrieved on: 
Monday, October 9, 2023
Page, Doctor of Philosophy, Anxiety, Cognitive behavioral therapy, Cerebrovascular disease, Sleep, Sleep medicine, Nation, Therapy, Psychology, Ageing, University, Dave's Picks Volume 38, Digital, Comorbidity, Disease, Cancer, Randomized controlled trial, Brain damage, Spectrum, Insomnia, Meta-analysis, DSM-IV codes, Journal of Affective Disorders, Research, Depression, SAN, Survivor, RCT, CBT, Nuffield Department of Population Health, ASCO, WSO, PMID, Disability, Systematic review, Canadian International Council, PMCID, Neurorehabilitation and Neural Repair, University of Oxford, Patient, Pharmaceutical industry, Nursing, Dietary supplement, Sleepio, Stroke

SAN FRANCISCO and OXFORD, England, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Big Health, the leader in digital therapeutics for the most common mental health conditions, announced today the publication of two, peer-reviewed studies demonstrating the effects of its flagship digital insomnia treatment Sleepio in individuals with co-morbid insomnia and clinically significant anxiety as well as in stroke survivors. 

Key Points: 
  • Digital cognitive behavioral therapy (dCBT) has long been evidenced as an effective treatment for insomnia and anxiety — key findings from these studies provide new insights into Sleepio's impact.
  • In a separate study among stroke survivors, 71% achieved remission using Sleepio compared to 30% of control participants.
  • Individuals with insomnia are three times more likely to develop anxiety than healthy sleepers.
  • [1] Additionally, comorbid insomnia and anxiety are associated with greater severity of both conditions — as well as increased symptoms of depression and poorer physical health.

First-of-Its-Kind Partnership Provides Free Access to Digital Mental Health Treatments for All Newly Diagnosed Cancer Patients in the United Kingdom

Retrieved on: 
Tuesday, July 26, 2022
Health Technology, Health, Oncology, Mental Health, Regulation of tobacco by the U.S. Food and Drug Administration, Generalized anxiety disorder, National Institute for Health and Care Excellence, University, COVID-19, United Kingdom, Labour government, Research, Food, Web browser, Macmillan Cancer Support, McMillan, Ageing, National Institute, Partnership, University of Oxford, Gold, Randomized controlled trial, Policy, Cognitive behavioral therapy, NHS, Depression, CBT, Cancer, Self-management, NICE, Quality of life, CE, Mental health, Sleep, FDA, Johns Hopkins University, Patient, Isabella Tree, NHS Scotland, Therapy, Health, Innovation, Lists of diseases, Anxiety, United States Public Health Service, Medical imaging, Pharmaceutical industry, Health insurance, Birth control, Daylight, Sleepio, Insomnia, Populus

Newly diagnosed cancer patients across the United Kingdom (UK) are now able to easily access innovative and effective treatments to support their mental health thanks to a new partnership between Macmillan Cancer Support and digital therapeutics company Big Health, makers of Sleepio and Daylight[i].

Key Points: 
  • Newly diagnosed cancer patients across the United Kingdom (UK) are now able to easily access innovative and effective treatments to support their mental health thanks to a new partnership between Macmillan Cancer Support and digital therapeutics company Big Health, makers of Sleepio and Daylight[i].
  • The partnership delivers on a shared vision to address the growing need to provide rapid, equitable mental health support to newly diagnosed cancer patients.
  • The partnership between Macmillan and Big Health will provide newly diagnosed cancer patients aged 18 and older residing in England, Wales, and Northern Ireland free access to Sleepio for insomnia and Daylight for anxiety to manage their mental health needs.
  • It also provides an option for those people with cancer who dont want to, or arent able to, access in-person mental health support.

Sleepio Is the First-Ever Digital Therapeutic to Receive NICE Guidance, Confirming Clinical and Cost Effectiveness

Retrieved on: 
Friday, May 20, 2022
Managed Care, General Health, Health, Mental Health, NHS, Insomnia, Digital, Smartphone, Self-management, National Institute for Health and Care Excellence, CBT, Isabella Tree, Generalized anxiety disorder, Ageing, Regulation of tobacco by the U.S. Food and Drug Administration, Policy, Food, National Institute, Board of directors, Patient, Oxford Health NHS Foundation Trust, CE, UnitedHealth Group, NICE, United Kingdom, FDA, Thames Valley, Anxiety, National Health Service (England), Innovation, Standard of care, Therapy, Innovate UK, Sleep hygiene, Mental health, Lists of diseases, Oxford, Diagnosis, Committee, National Health Service, Web browser, CEO, Pharmaceutical industry, Health insurance, Medical device, Medicine, Sleepio

Peer-reviewed clinical trials show Sleepio helps 76% of patients to achieve clinical improvement in insomnia.

Key Points: 
  • Peer-reviewed clinical trials show Sleepio helps 76% of patients to achieve clinical improvement in insomnia.
  • Big Health co-founder and Chief Scientist Professor Colin Espie said: We are delighted that Sleepio has become the first-ever digital therapeutic to receive NICE guidance after rigorous evaluation.
  • Digital therapeutics arent wellness apps; they are proper treatments backed by data and clinical evidence, fit for assessment by world-leading bodies like NICE.
  • Sleepio is a clinically-evidenced digital therapeutic for insomnia developed by world-renowned clinical psychologist and sleep expert Professor Colin Espie.

First-of-its-Kind Study Demonstrates Digital Therapeutic Significantly Improves Sleep and Mental Health for Stroke Patients

Retrieved on: 
Wednesday, May 4, 2022
Cardiology, Software, Biotechnology, Health, Mental Health, Technology, Clinical Trials, Mobile, Wireless, Policy, Sleep, Rehabilitation, National Institute for Health and Care Excellence, Behavioral medicine, University, CBT, Twitter, Cognitive behavioral therapy, Nuffield Department of Population Health, NICE, Stroke, Food, Depression, Research, Patient, Clinical trial, FDA, Therapy, Anxiety, Regulation of tobacco by the U.S. Food and Drug Administration, ESO, Wellcome Trust, Ageing, LinkedIn, Lists of diseases, Memory, Survivor, Mental health, Insomnia, Pharmacy, Generalized anxiety disorder, Risk, National Institute, Pharmaceutical industry, Sleepio

Big Health , a digital therapeutics company dedicated to helping millions back to good mental health, participated in a new, first-of-its-kind study in collaboration with the University of Oxford evaluating how a digital therapeutic for insomnia can benefit stroke patients with self-reported sleep issues.

Key Points: 
  • Big Health , a digital therapeutics company dedicated to helping millions back to good mental health, participated in a new, first-of-its-kind study in collaboration with the University of Oxford evaluating how a digital therapeutic for insomnia can benefit stroke patients with self-reported sleep issues.
  • Preliminary outcomes found more than 48% of participants who utilized Sleepio Big Healths digital therapeutic for insomnia experienced clinical improvement in sleep during post-stroke rehabilitation.
  • The study findings will be presented on May 4-6 at the European Stroke Organisation (ESO) conference being held in Lyon, France.
  • A 2019 study noted approximately half of stroke survivors have insomnia, which is associated with higher rates of incident stroke and worse post-stroke outcomes.

Scotland Becomes First Country in the World to make Digital Therapeutics for Anxiety and Insomnia Available Nationally

Retrieved on: 
Wednesday, October 13, 2021
Women, Men, General Health, Health, FDA, Mental Health, Medical Devices, Consumer, People, University, Mental health, Insomnia, NHS Scotland, Colin Espie, Health, COVID-19, Food, Computerize, Scottish Government, Sleep, Labour government, Adoption, FDA, CBT, Â, CE, Lists of diseases, Sleepio, Regulation of tobacco by the U.S. Food and Drug Administration, Social, Scottish people, NHS, Policy, Therapy, Sleep medicine, Ageing, Solution, Covert conditioning, Anxiety, Self-management, United States Public Health Service, Minister for Mental Wellbeing and Social Care, Generalized anxiety disorder, Patient, Isabella Tree, Technology, Mental, Pharmaceutical industry, Medicine

Through this new service, Scotland becomes the first country to implement fully digital solutions that provide instant help for anxiety and insomnia nationwide and at no cost to the user.

Key Points: 
  • Through this new service, Scotland becomes the first country to implement fully digital solutions that provide instant help for anxiety and insomnia nationwide and at no cost to the user.
  • People across all 14 NHS Scotland Health Board Areas will have 24/7 instant access to Big Healths digital therapeutics as the first-line treatment for anxiety and insomnia, effectively scaling access to care through the Computerised CBT (cCBT) & Digital Mental Health programme .
  • In October 2020, the Scottish Government made Daylight and Sleepio available across five NHS Health Boards.
  • By increasing the options for evidenced-based mental health help at the point of need, Scotland is the only country to truly exploit the potential for digital therapeutics.